Send Inquiry
400 MG Imatinib Tablets IP
500 INR/Box
Product Details:
- Origin of Medicine India
- Drug Type General Medicines
- Physical Form Tablets
- Dosage 400 mg
- Dosage Guidelines As per suggestion
- Storage Instructions Keep In A Cool And Dry Place
- Click to View more
X
400 MG Imatinib Tablets IP Price And Quantity
- 500 INR/Box
- 50 Box
400 MG Imatinib Tablets IP Product Specifications
- India
- General Medicines
- 400 mg
- Keep In A Cool And Dry Place
- As per suggestion
- Tablets
400 MG Imatinib Tablets IP Trade Information
- Cash in Advance (CID)
- 5000 Box Per Month
- 2-10 Days
- Asia Australia Central America North America South America Eastern Europe Western Europe Middle East Africa
- All India
Product Description
400 MG Imatinib Tablets IP is a general medicine that comes in tablet form. It is manufactured in India and is used to treat certain types of cancer. The dosage of each tablet is 400 mg, and it should be stored in a cool and dry place. The dosage guidelines for this medicine should be followed as per the suggestions of a medical professional.
FAQs of 400 MG Imatinib Tablets IP:
Q: What is the recommended dosage for 400 MG Imatinib Tablets IP?
A: The dosage guidelines for this medicine should be followed as per the suggestions of a medical professional.Q: What is the physical form of 400 MG Imatinib Tablets IP?
A: It comes in tablet form.Q: What is the drug type of 400 MG Imatinib Tablets IP?
A: It is a general medicine.Q: Where is 400 MG Imatinib Tablets IP manufactured?
A: It is manufactured in India.Q: How should 400 MG Imatinib Tablets IP be stored?
A: It should be kept in a cool and dry place.Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
Other Products in 'Pharmaceutical Tablets' category
We are accepting only foreign inquiries.
LEOWIN HEALTHCARE LLP
All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.
Developed and Managed by Infocom Network Private Limited.
